NDC Compounded Drug 61141-4837-1 Bupivacaine Hydrochloride; Fentanyl Citrate

Injection, Solution Epidural

Table of Contents

    1. Compounded Product Information
    2. Frequently Asked Questions

Compounded Drug Product Information

NDC Product Code 61141-4837
NDC Package Code 61141-4837-1
11-Digit NDC Billing Format NDC Format for Billing
For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.		 61141483701
Package Description 150 mL in 1 BAG
Product Type What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.		 Human Compounded Drug
Proprietary Name What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.		 Fentanyl Citrate2mcg/ml With Bupivacaine Hcl 0.125%, 150ml Bag
Non-Proprietary Name What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.		 Fentanyl Citrate, Bupivacaine Hcl
Substance Name What is the Substance Name?
An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.		 Bupivacaine Hydrochloride; Fentanyl Citrate
Dosage Form Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Route Name Epidural - Administration upon or over the dura mater.
Marketing Category OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Code 61141
Labeler Name What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.		 Medi-fare Drug
Substance Name Bupivacaine Hydrochloride; Fentanyl Citrate
Active Ingredients Information 1.25 mg/1 mL; 2 ug/1 mL
DEA Schedule What is the Drug Enforcement Administration (DEA) CII Schedule?
The controlled substances in the CII schedule have a high abuse potential with severe psychological or physical dependence liability, but have accepted medical use in the United States. Schedule CII controlled substances include certain narcotic, stimulant, and depressant drugs. 		Schedule II (CII) Substances
Reporting Period 2021-2

Frequently Asked Questions

What is the NDC number assigned to Fentanyl Citrate2mcg/ml With Bupivacaine Hcl 0.125%, 150ml Bag?

Fentanyl Citrate2mcg/ml With Bupivacaine Hcl 0.125%, 150ml Bag was assigned by its manufacturer with NDC product code 61141-4837. This product is a drug classified as a human compounded drug. Compounded drugs are medications created by combining or altering existing drugs to meet the specific needs of certain patients. The NDC directory only includes information about compounded drugs from facilities that choose to assign NDC numbers to their products.

Which are the NDC package codes for Fentanyl Citrate2mcg/ml With Bupivacaine Hcl 0.125%, 150ml Bag?

The NDC package code 61141-4837-1 was assigned to a 150 mL in 1 BAG of bupivacaine hydrochloride; fentanyl citrate administered epidural via injection, solution.

Who manufactures this product?

Fentanyl Citrate2mcg/ml With Bupivacaine Hcl 0.125%, 150ml Bag is manufactured by an outsourced facility and labeled by Medi-fare Drug. All compounded drugs included in the NDC directory are classified as "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)". Outsourcing facilities are a type of drug compounding facility regulated under Section 503B of the FD&C Act could be eligible for exemptions from drug registration if they meet all the conditions specified under Section 503B.